topotecan has been researched along with Stomach Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H | 1 |
| Du, HZ; Gao, YS; Li, RM; Luo, XJ; Qian, CM; Sun, L; Wang, JS; Wei, D; Yu, BY; Yu, XW; Yuan, ST | 1 |
| Chen, X; Du, H; Hou, X; Li, H; Lin, S; Liu, Y; Lu, L; Sun, L; Yu, X; Yuan, S; Zhan, M | 1 |
| Du, HZ; He, JY; Jiang, JW; Li, ZZ; Liu, Y; Sun, L; Wang, L; Yuan, ST; Zhang, BJ; Zhao, TL | 1 |
| Du, HZ; Feng, SY; Li, RM; Lin, S; Luo, XJ; Qian, CM; Sun, L; Yu, BY; Yu, XW; Yuan, ST; Zhang, LY; Zhao, RP | 1 |
| Ji, YB; You, QD; Zhou, JH; Zuo, MX | 1 |
| Andreopoulou, E; Blank, S; Chen, T; Curtin, J; Hochster, H; Liebes, L; Muggia, F; Wallach, R | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Balcerzak, SP; Benedetti, JK; Burris, HA; Macdonald, JS | 1 |
| Ilson, DH; Kelsen, DP; Quan, V; Saltz, LB; Schwartz, GK | 1 |
| Adler, H; Buckley, M; Cho, J; Dar, K; Fry, D; Hochster, H; Kim, T; Liebes, L; Pease, D; Potmesil, M; Zeleniuch-Jacquotte, A | 1 |
5 trial(s) available for topotecan and Stomach Neoplasms
| Article | Year |
|---|---|
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Lactones; Middle Aged; Neutropenia; Ovarian Neoplasms; Remission Induction; Stomach Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2011 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Leukopenia; Male; Middle Aged; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Stomach Neoplasms; Topotecan; Tumor Protein, Translationally-Controlled 1 | 1997 |
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Autoantibodies; Autoantigens; Biomarkers; Biopsy; Breast Neoplasms; Cell Line; DNA Topoisomerases, Type I; Endometrial Neoplasms; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; HeLa Cells; Humans; Lung Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Pancreatic Neoplasms; Scleroderma, Systemic; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
6 other study(ies) available for topotecan and Stomach Neoplasms
| Article | Year |
|---|---|
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2022 |
Synergistic combination of DT-13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC-823 cells via NM IIA/EGFR/HK II axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Drug Synergism; Endocytosis; ErbB Receptors; Female; Glycolysis; Hexokinase; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Nonmuscle Myosin Type IIA; RNA, Small Interfering; Saponins; Stomach Neoplasms; Topotecan; Xenograft Model Antitumor Assays | 2019 |
DT-13 synergistically potentiates the sensitivity of gastric cancer cells to topotecan via cell cycle arrest in vitro and in vivo.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Saponins; Stomach Neoplasms; Topotecan | 2018 |
Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Topics: Amino Acid Transport System ASC; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutamine; Glutathione; Humans; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Minor Histocompatibility Antigens; Mitochondria; Molecular Targeted Therapy; Oxidative Stress; Stomach Neoplasms; Topotecan | 2019 |
Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Endocytosis; ErbB Receptors; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nonmuscle Myosin Type IIA; Saponins; Signal Transduction; Stomach Neoplasms; Topotecan; Xenograft Model Antitumor Assays | 2016 |
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxazoles; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Protein p53 | 2008 |